Skip to main content
. 2024 Feb 22;14(6):1048–1063. doi: 10.1158/2159-8290.CD-23-1060

Figure 1.

Figure 1. Overview of the study and the analysis of cell-free methylomes and fragmentomes. A, CONSORT diagram for cfMeDIP-seq analysis within the INSPIRE study. B, We performed cfMeDIP-seq in a cohort of patients with various solid tumors treated with pembrolizumab. We computed CSM scores and fragment-length scores through joint analysis of the methylome and fragmentome. C, CSM and (D) FLS were significantly higher in samples from patients with cancer than those from normal controls, by Wilcoxon rank-sum tests. Boxplots show median and quartiles.

Overview of the study and the analysis of cell-free methylomes and fragmentomes. A, CONSORT diagram for cfMeDIP-seq analysis within the INSPIRE study. B, We performed cfMeDIP-seq in a cohort of patients with various solid tumors treated with pembrolizumab. We computed CSM scores and fragment-length scores through joint analysis of the methylome and fragmentome. C, CSM and (D) FLS were significantly higher in samples from patients with cancer than those from normal controls, by Wilcoxon rank-sum tests. Boxplots show median and quartiles.